Australia's most trusted
source of pharma news
Wednesday, 03 December 2025
Posted 3 December 2025 AM
A Melbourne-based company is taking on Johnson & Johnson in a multi-billion dollar market.
InhaleRx has announced it will begin developing SRX-25, an oral fixed-dose combination therapy of esketamine and an CYP450 inhibitor for Treatment-Resistant Depression (TRD).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.